Reaction

Injection Site Injury reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,412 reports · 49 co-occurring drugs

As of the last recalculation, Injection Site Injury appears in 5,412 FAERS reports alongside 49 co-occurring drug terms. The strongest observed disproportionality signal is TIRZEPATIDE (PRR 47.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tirzepatide	1,463	47.3	47.8
Galcanezumab-Gnlm	195	24.7	24.8
Dulaglutide	362	16.8	16.8
Epinephrine	113	6.8	6.8
Ixekizumab	62	6.5	6.5
Teriparatide	174	6.1	6.1
Glatiramer Acetate	88	5.7	5.7
Insulin Human	54	5.3	5.3
Fremanezumab-Vfrm	14	4.7	4.7
Insulin Lispro	160	4.6	4.6
Insulin Glargine	272	4.4	4.4
Alirocumab	25	3.8	3.8
Naltrexone	30	3.8	3.8
Adalimumab	602	3.6	3.6
Interferon Beta-1B	17	3.4	3.4
Evolocumab	141	3.4	3.4
Human Insulin	11	3.4	3.4
Octreotide Acetate	26	3.3	3.3
Benralizumab	17	3.3	3.3
Erenumab-Aooe	45	3.2	3.2
Insulin Aspart	51	3.0	3.0
Peginterferon Beta-1A	10	2.9	2.9
Insulin Degludec	16	2.6	2.6
Somatropin	49	2.6	2.6
Interferon Beta-1A	123	2.5	2.5
Tamsulosin Hydrochloride	13	2.5	2.5
Belimumab	20	2.4	2.4
Metformin Er 500 Mg	180	2.3	2.3
Metformin Er 750 Mg	180	2.3	2.3
Goserelin	8	2.3	2.3
Insulin Glulisine	6	2.3	2.3
Glimepiride	22	2.2	2.2
Risankizumab-Rzaa	44	2.1	2.1
Etanercept	310	2.1	2.1
Lanreotide Acetate	4	2.0	2.0
Asfotase Alfa	5	1.9	1.9
Exenatide	26	1.9	1.9
Abaloparatide	14	1.8	1.8
Nemolizumab-Ilto	5	1.5	1.5
Secukinumab	62	1.5	1.5
Liraglutide	19	1.5	1.5
Cabotegravir	3	1.4	1.4
Guselkumab	13	1.4	1.4
Aflibercept	10	1.2	1.2
Ofatumumab	10	1.2	1.2
Onabotulinumtoxina	23	1.1	1.1
Canagliflozin	8	1.0	1.0
Dupilumab	96	0.8	0.8
Sarilumab	5	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.